Compare ADMA Biologics Inc (ADMA) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Petróleo Brasileiro SA — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Petróleo Brasileiro SA trades at $18 (market cap $114.31B). The key difference: Petróleo Brasileiro SA is far larger — about 52.4× ADMA Biologics Inc's market cap, and Petróleo Brasileiro SA pays a 9.62% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | PBR | |
|---|---|---|
Market Cap | $2.18B | $114.31B |
Sector | Health | Technology |
52-Week High | $20.38 | $22.03 |
52-Week Low | $7.60 | $11.54 |
Enterprise Value | $2.25B | $174.73B |
Dividend Yield | — | 9.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
PBR trades at $17.96, down 3.02% today, with bearish technical signals but strong fundamentals. The company reported robust Q2 2026 results with record production of 3.34 million boe/day and net earnings surging 120% year-over-year. Valuation metrics remain attractive with P/E of 4.63 and ROE of 30.77%. Analyst consensus is bullish with 11 buy ratings out of 22 total coverage.
PBR presents a compelling value opportunity with strong profitability and dividend yield, though regulatory uncertainty and oil price volatility pose risks. The company's production growth trajectory and cost-efficient pre-salt assets support long-term upside potential despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
